Biblio
“APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”, J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
, “Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.”, J Clin Invest, vol. 122, no. 4, pp. 1316-38, 2012.
, “Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”, Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
, “Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1205-15, 2016.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Impaired Autophagy in APOE4 Astrocytes.”, J Alzheimers Dis, vol. 51, no. 3, pp. 915-27, 2016.
, “The Genetic Variability of UCP4 Affects the Individual Susceptibility to Late-Onset Alzheimer's Disease and Modifies the Disease's Risk in APOE-ɛ4 Carriers.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1265-74, 2016.
, “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
, “Age and its association with low insulin and high amyloid-β peptides in blood.”, J Alzheimers Dis, vol. 49, no. 1, pp. 129-37, 2016.
, “MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.”, J Alzheimers Dis, vol. 49, no. 2, pp. 343-52, 2016.
, “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
, “Increase of α-Secretase ADAM10 in Platelets Along Cognitively Healthy Aging.”, J Alzheimers Dis, vol. 50, no. 3, pp. 817-26, 2016.
, “Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 567-76, 2016.
, “Decreased Inter-Hemispheric Functional Connectivity in Cognitively Intact Elderly APOE ɛ4 Carriers: A Preliminary Study.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1137-48, 2016.
, “Apolipoprotein E Related Co-Morbidities and Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 935-48, 2016.
, “Apolipoprotein ɛ4 is Associated with Dementia and Cognitive Impairment Predominantly Due to Alzheimer's Disease and Not with Vascular Cognitive Impairment: A Singapore-Based Cohort.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1111-8, 2016.
, “Diversity of Cognitive Phenotypes Associated with C9ORF72 Hexanucleotide Expansion.”, J Alzheimers Dis, vol. 52, no. 1, pp. 25-31, 2016.
, “Association of Frontotemporal Dementia GWAS Loci with Late-Onset Alzheimer's Disease in a Northern Han Chinese Population.”, J Alzheimers Dis, vol. 52, no. 1, pp. 43-50, 2016.
, “Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 52, no. 1, pp. 271-81, 2016.
, “What is the Relationship of Traumatic Brain Injury to Dementia?”, J Alzheimers Dis, vol. 57, no. 3, pp. 667-681, 2017.
, “Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 309-320, 2018.
,